|
業務類別
|
-- |
|
業務概覽
|
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China. |
| 公司地址
| 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000 |
| 電話號碼
| +86 51285557777 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ascentagepharma.com |
| 員工數量
| 567 |
| Dr. Dajun Yang, M.D.,PhD |
Chairman of the board and Chief Executive Officer |
美元 5.85M |
29/04/2026 |
| Mr. Thomas J. Knapp |
Senior Vice President and General Counsel |
-- |
29/04/2026 |
| Dr. Veet Misra, PhD |
Chief Financial Officer |
-- |
29/04/2026 |
| Mr. Jin Cao, M.D. |
Head of Finance, China |
-- |
29/04/2026 |
| Dr. Yifan Zhai, M.D.,PhD |
Chief Medical Officer |
-- |
29/04/2026 |
|
|
| Dr. David Sidransky, M.D. |
Independent Director |
29/04/2026 |
| Ms. Marina S. Bozilenko |
Independent Director |
29/04/2026 |
| Mr. Changqing Ye |
Independent Director |
29/04/2026 |
| Dr. Debra Yu, M.D. |
Independent Director |
29/04/2026 |
| Dr. Dajun Yang, M.D.,PhD |
Chairman of the board and Chief Executive Officer |
29/04/2026 |
| Dr. Shaomeng Wang, PhD |
Director |
29/04/2026 |
| Dr. Simon Dazhong Lu, PhD |
Independent Director |
29/04/2026 |
| Mr. Wei Ren |
Independent Director |
29/04/2026 |
| Dr. Marc E. Lippman,M.D. |
Independent Director |
29/04/2026 |
|
|
|
|
